使用来自IFN-γ结合蛋白和偏向激动剂的结构功能信息来解免疫刺激和免疫抑制活动
Lucas Mendes-Monteiro1, Abel Viejo-Borbolla2
1Institute of Virology, Hannover Medical School, Hannover 30625, Germany.
Trends in immunology
|March 18, 2025
概括
科学家们的目标是通过研究病毒蛋白来设计新的干扰素玛 (IFN-γ) 激动剂. 这种方法可以减少IFN-γ.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 结构生物学 结构生物学
背景情况:
- 干扰素- (IFN-γ) 是一种关键的抗病毒细胞因子,协调免疫反应.
- IFN-γ的双重免疫刺激和免疫抑制作用限制了其临床应用.
- 病毒通常编码蛋白质,这些蛋白质与其受体 (IFNGR) 结合并阻止IFN-γ的相互作用.
研究的目的:
- 设计具有微调活性的新型IFN-γ激动剂.
- 为了利用病毒蛋白与IFN-γ的相互作用的见解.
- 为了减少IFN-γ治疗的免疫抑制和毒性作用.
主要方法:
- 分析结合IFN-γ的病毒蛋白的结构和机制数据.
- 研究 varicella zoster 病毒糖蛋白 C 与 IFN-γ 的相互作用机制.
- 利用基于IFN-γ - IFNGR复合结构的偏向IFN-γ激动剂的信息.
主要成果:
- 疹病毒糖蛋白C与IFN-γ结合,并诱导特定的ISG.
- 这种相互作用模仿了偏向的IFN-γ激动剂的影响.
- 结构和机制的洞察力可以指导激进的设计.
结论:
- 设计基于病毒蛋白相互作用的新型IFN-γ激动剂是可行的.
- 这一策略可以带来更好的治疗药物,并减少副作用.
- 向IFN-γ - IFNGR通路为新的抗病毒和免疫调节疗法提供了潜力.
相关概念视频
T Cell Types and Functions
730
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
730
The Two-State Receptor Model
1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.8K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K


